Pfizer Cut the Vaccine Production Dose in Half

Pfizer Cut the Vaccine Production Dose in Half Pfizer cut the vaccine production dose in half. The company lowered its target from 100 million doses to 50 million doses. Pfizer, which set a production target of 100 million doses in 2020 for the vaccine developed with the German company BioNTech, cut its target by half. This decision of the company shocked the markets waiting for production with enthusiasm. Making a statement on the subject, the company spokesperson stated that many factors, including the process of procuring the large-scale raw material needed in the production of vaccines, were effective in the slowdown of production. In addition, the company spokesperson reported that Pfizer has completed the process of increasing the scale of production and is producing at a fast pace. The use of the coronavirus vaccine, which will be administered in two doses and developed with a new technology called "carrier RNA", was approved in the UK this week, and an urgent approval application was made to the US Food and Drug Administration (FDA). In clinical tests performed on 44 thousand subjects, the vaccine was proven to be 95 percent effective in preventing coronavirus (Covid-19) symptoms.